Skip to main content
Erschienen in: American Journal of Clinical Dermatology 3/2001

01.06.2001 | Adis New Drug Profile

Topical Eflornithine

verfasst von: Julia A. Barman Balfour, Karen McClellan

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 3/2001

Einloggen, um Zugang zu erhalten

Abstract

▴ Eflornithine is a specific, irreversible inhibitor of the enzyme ornithine decarboxylase which is thought to slow hair growth by inhibiting this enzyme in hair follicles.
▴ Percutaneous absorption of eflornithine in women with unwanted facial hair (hirsutism) was <1% when the 15% cream was applied twice daily to a shaved 50cm2 area of skin under the chin. ▴ In clinical studies in women with excessive, unwanted facial hair, eflornithine 15% cream was superior to placebo in reducing hair growth, as demonstrated by objective and subjective methods, after 2 to 8 weeks’ treatment.
▴ After 24 weeks’ treatment, 58% of eflornithine and 34% of placebo recipients had at least some improvement in facial hirsutism (for the purposes of this analysis all patients not assessed at week 24 were considered to be worse or to have no improvement). In addition, 32 versus 8% of patients were judged to be successfully treated (at least marked improvement). Hair growth returned to pretreatment rates within 8 weeks of stopping treatment.
▴ Use of a self-assessment questionnaire to assess the effect of study treatment on 6 aspects of patient well-being showed that eflornithine reduced the mean level of overall discomfort and bother by 33 versus 15% in placebo recipients.
▴ Adverse events mostly affected the skin. Only burning/stinging/ tingling was markedly more common with eflornithine than with placebo.
Literatur
2.
Zurück zum Zitat Conn J.J., Jacobs H.S. Managing hirsutism in gynaecological practice. Br J Obstet Gynaecol 1998 Jul; 105: 687–696PubMedCrossRef Conn J.J., Jacobs H.S. Managing hirsutism in gynaecological practice. Br J Obstet Gynaecol 1998 Jul; 105: 687–696PubMedCrossRef
3.
Zurück zum Zitat Falsetti L., Gambera A., Platto C., et al. Management of hirsutism. Am J Clin Dermatol 2000; 1: 89–99PubMedCrossRef Falsetti L., Gambera A., Platto C., et al. Management of hirsutism. Am J Clin Dermatol 2000; 1: 89–99PubMedCrossRef
4.
Zurück zum Zitat Conn J.J., Jacobs H.S. The clinical management of hirsutism. Eur J Endocrinol 1997 Apr; 136: 339–348PubMedCrossRef Conn J.J., Jacobs H.S. The clinical management of hirsutism. Eur J Endocrinol 1997 Apr; 136: 339–348PubMedCrossRef
5.
Zurück zum Zitat Mosby’s GenRx. Update 3, 2000 ed. Available from: URL:http/www.mosbysgenrx.com [Accessed 2000 Oct 24] Mosby’s GenRx. Update 3, 2000 ed. Available from: URL:http/www.mosbysgenrx.com [Accessed 2000 Oct 24]
6.
Zurück zum Zitat Bristol-Myers Squibb Eflornithine prescribing information. Princeton (NJ): 2000 Jul Bristol-Myers Squibb Eflornithine prescribing information. Princeton (NJ): 2000 Jul
7.
Zurück zum Zitat Shander D., Funkhouser M.G., Ahluwalia G.S., et al. Pharmacology of hair growth inhibition by topical treatment with eflornithine-HCl monohydrate (DFMO) using the hamster flank organ model [abstract no. 123]. American Academy of Dermatology 59th Annual Meeting; 2001 Mar 2–7; Washington, DC Shander D., Funkhouser M.G., Ahluwalia G.S., et al. Pharmacology of hair growth inhibition by topical treatment with eflornithine-HCl monohydrate (DFMO) using the hamster flank organ model [abstract no. 123]. American Academy of Dermatology 59th Annual Meeting; 2001 Mar 2–7; Washington, DC
8.
Zurück zum Zitat Shander D., Funkhouser M.G., Harrington F.E., et al. Clinical dose range studies with topical application of the ornithine decarboxylase inhibitor eflornithine HCl ((alpha-(difluoromethyl)-DL-ornithine; DFMO) in women with facial hirsutism [abstract no. 228]. American Academy of Dermatology 59th Annual Meeting; 2001 Mar 2–7; Washington, DC Shander D., Funkhouser M.G., Harrington F.E., et al. Clinical dose range studies with topical application of the ornithine decarboxylase inhibitor eflornithine HCl ((alpha-(difluoromethyl)-DL-ornithine; DFMO) in women with facial hirsutism [abstract no. 228]. American Academy of Dermatology 59th Annual Meeting; 2001 Mar 2–7; Washington, DC
9.
Zurück zum Zitat Malhotra B., Palmisano M., Schrode K., et al. Percutaneous absorption, pharmacokinetics and dermal safety of eflornithine 15% cream in hirsute women [poster]. American Academy of Dermatology 58th Annual Meeting; 2000 Mar 10–15; San Francisco Malhotra B., Palmisano M., Schrode K., et al. Percutaneous absorption, pharmacokinetics and dermal safety of eflornithine 15% cream in hirsute women [poster]. American Academy of Dermatology 58th Annual Meeting; 2000 Mar 10–15; San Francisco
10.
Zurück zum Zitat Huber F., Schrode K., Staszak J., et al. Use of a video imaging system to obtain hair measurement data in controlled clinical trials evaluating the safety and efficacy of eflornithine 15% cream in the treatment of excessive facial hair in women [poster]. American Academy of Dermatolgy 58th Annual Meeting; 2000 Mar 10–15; San Francisco Huber F., Schrode K., Staszak J., et al. Use of a video imaging system to obtain hair measurement data in controlled clinical trials evaluating the safety and efficacy of eflornithine 15% cream in the treatment of excessive facial hair in women [poster]. American Academy of Dermatolgy 58th Annual Meeting; 2000 Mar 10–15; San Francisco
11.
Zurück zum Zitat Schrode K., Huber F., Staszak J., et al. Randomized, double-blind, vehicle-controlled safety and efficacy evaluation of eflornithine 15% cream in the treatment of women with excessive facial hair [poster]. American Academy of Dermatology 58th Annual Meeting; 2000 Mar 10–15, San Francisco Schrode K., Huber F., Staszak J., et al. Randomized, double-blind, vehicle-controlled safety and efficacy evaluation of eflornithine 15% cream in the treatment of women with excessive facial hair [poster]. American Academy of Dermatology 58th Annual Meeting; 2000 Mar 10–15, San Francisco
12.
Zurück zum Zitat Schrode K., Huber F., Staszak J., et al. Evaluation of the long-term safety of eflornithine 15% cream in the treatment of women with excessive facial hair [poster]. American Academy of Dermatology 58th Annual Meeting; 2000 Mar 10–15; San Francisco Schrode K., Huber F., Staszak J., et al. Evaluation of the long-term safety of eflornithine 15% cream in the treatment of women with excessive facial hair [poster]. American Academy of Dermatology 58th Annual Meeting; 2000 Mar 10–15; San Francisco
13.
Zurück zum Zitat Huber F., Schrode K., Staszak J., et al. Outcome of a qulaity of life assessment used in clinical trials for hirsute women treated with topical eflornithine cream [poster]. American Academy of Dermatology 58th Annual Meeting; 2000 Mar 10–15; San Francisco Huber F., Schrode K., Staszak J., et al. Outcome of a qulaity of life assessment used in clinical trials for hirsute women treated with topical eflornithine cream [poster]. American Academy of Dermatology 58th Annual Meeting; 2000 Mar 10–15; San Francisco
14.
Zurück zum Zitat Data on file, Bristol-Myers Squibb, 2000 Nov. Data on file, Bristol-Myers Squibb, 2000 Nov.
Metadaten
Titel
Topical Eflornithine
verfasst von
Julia A. Barman Balfour
Karen McClellan
Publikationsdatum
01.06.2001
Verlag
Springer International Publishing
Erschienen in
American Journal of Clinical Dermatology / Ausgabe 3/2001
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI
https://doi.org/10.2165/00128071-200102030-00009

Weitere Artikel der Ausgabe 3/2001

American Journal of Clinical Dermatology 3/2001 Zur Ausgabe

Review Article

Vitiligo

Adis New Drug Profile

Topical Eflornithine

Adis New Drug Profile

Topical Eflornithine

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.